Recent advances of CRISPR-based gene editing technologies and delivery strategies
Artificial Cells, Nanomedicine, and Biotechnology · Published 2026-07-29 · DOI 10.1080/21691401.2026.2702869
Free full text
Authors (7)
Fanyu Xue, Zixuan Xin, Gaojie Wang, Jiayin Xing, Hengxin Han, Xiangxiang Zhao, Ningning Song
Abstract
CRISPR technology is a powerful tool for gene editing, in which the efficient delivery of living target cells allows it to show great clinical potential. At present, the commonly used in vivo delivery strategies mainly include biological methods (AAV, VLP, SEND) and chemical methods (LNP), which subtly deliver gene editors to living target cells safely and efficiently from different ways. However, existing delivery systems have different extents of limitations in terms of editing efficiency, immunogenicity, half-life, etc., so developing optimized delivery systems is the key to fully realizing the potential of CRISPR-Cas system for intracellular gene editing. In order to fully understand the advantages of different delivery strategies to maximize the ability to help CRISPR systems choose delivery methods, we conducted a systematic review. In this paper, we introduce the types, principles and characteristics of gene editing systems in order to understand their requirements for delivery tools. We focus on describing the type, principle, load, immunogenicity, specificity, toxicity, etc. of the delivery system, so as to fully analyse its advantages and disadvantages for the selection of different editing environments. This review aims to provide new insights to facilitate appropriate delivery systems or improve the efficacy of existing systems.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Publication details
- Year
- 2026
Citation
Xue, F., Xin, Z., Wang, G., et al. (2026). Recent advances of CRISPR-based gene editing technologies and delivery strategies. Artificial Cells, Nanomedicine, and Biotechnology. https://doi.org/10.1080/21691401.2026.2702869
Related articles
- Molecular mechanisms of phytochemicals from Zanthoxylum nitidum (Roxb.) DC. against hepatocellular carcinoma: insights from network pharmacology, molecular docking, and bioinformatics · Artificial Cells, Nanomedicine, and Biotechnology · 2026 · Same journal
- Antimicrobial properties and bioactivity of zirconia-based biocomposites · Artificial Cells, Nanomedicine, and Biotechnology · 2025 · Same journal
- Human tendon stem/progenitor cell-derived extracellular vesicle production promoted by dynamic culture · Artificial Cells, Nanomedicine, and Biotechnology · 2025 · Same journal
- Characterization of genipin-crosslinked gelatin/PVA hydrogels and the chondroprotective influence of hydroxytyrosol: an In vitro study · Artificial Cells, Nanomedicine, and Biotechnology · 2026 · Same journal
- Identification of mitophagy-related biomarkers in human rheumatoid arthritis using machine learning models · Artificial Cells, Nanomedicine, and Biotechnology · 2025 · Same journal
- Multi-omics analysis of the potential association between ageing and rheumatoid arthritis and screening of potential therapeutic targets · Artificial Cells, Nanomedicine, and Biotechnology · 2025 · Same journal
- Cross-talk between diabetic nephropathy and bone loss: PBMCs-guided discovery of NLRP3-inflammatory signalling · Artificial Cells, Nanomedicine, and Biotechnology · 2025 · Same journal
- Exosome-mediated perturbation of the immune-bone metabolism axis: a mechanistic investigation into bone loss in a simulated microgravity environment · Artificial Cells, Nanomedicine, and Biotechnology · 2025 · Same journal
- Bio-Inspired lipid nanovesicles (iNVs) incorporating membrane proteins from healthy tendon stem cells for targeted protein restoration in tendinopathic in vitro model · Artificial Cells, Nanomedicine, and Biotechnology · 2026 · Same journal
- Novel anti-rheumatic potential of Eucalrobusone C: inhibition of rheumatoid arthritis fibroblast-like synoviocytes and metabolic reprogramming · Artificial Cells, Nanomedicine, and Biotechnology · 2026 · Same journal